1. Wiegand J, Van Bömmel F, Berg T. (2010). Management of chronic hepatitis B: status and challenges beyond treatment guidelines, Semin Liver Dis. 30: 361-377.
2. Piracha ZZ, Kwon H, Saeed U, Kim J, Jung J, Chwae YJ, Park S, Shin HJ, Kim K. (2018). Sirtuin 2 Isoform 1 Enhances Hepatitis B Virus RNA Transcription and DNA Synthesis through the AKT/GSK-3β/β-Catenin Signaling Pathway. J Virol. 92:e00955-18.
3. Saeed U, Kim J, Piracha ZZ, Kwon H, Jung J, Chwae YJ, Park S, Shin HJ, Kim K. (2019). Parvulin 14 and Parvulin 17 Bind to HBx and cccDNA and Upregulate Hepatitis B Virus Replication from cccDNA to Virion in an HBx-Dependent Manner. J Virol. 93:e01840-18.
4. Piracha ZZ, Saeed U, Kim J, Kwon H, Chwae YJ, Lee HW, Lim JH, Park S, Shin HJ, Kim K. An Alternatively Spliced Sirtuin 2 Isoform 5 Inhibits Hepatitis B Virus Replication from cccDNA by Repressing Epigenetic Modifications Made by Histone Lysine Methyltransferases. J Virol. 2020 Jul 30;94(16):e00926-20. doi: 10.1128/JVI.00926-20.
5. Ali SA, Donahue RM, Qureshi H, Vermund SH. (2009). Hepatitis B and hepatitis C in Pakistan: Prevalence and risk factors. Int J Infect Dis. 13: 9-19.
6. Reeves R. (2010). Nuclear functions of the HMG proteins. BiochimBiophys Acta. 1799: 3–14.
7. Karlsen TH, Melum E, Franke A. (2010). The utility of genome-wide association studies in hepatology. Hepatology. 51:1833–1842.
8. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C., et al. (2009). Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 461: 798–801.
9. Brennan P, Hainaut P, Boffetta P. (2011). Genetics of lung-cancer susceptibility. Lancet Oncol. 12: 399–408.
10. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, et al. (2015). Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 47: 373–380.
11. Yan Z, Tan S, Dan Y, Sun X, Deng G, Wang Y. (2012). Relationship between HLA-DP gene polymorphisms and clearance of chronic hepatitis B virus infections: case-control study and meta-analysis. Infect Genet Evol. 12: 1222-1228.
12. Deng CQ, Deng GH, Wang YM. (2005). eNOS gene 894G/T polymorphisms among patients infected with HBV. VirologicaSinica. 20: 476-479
14. Deng CQ, Deng GH, Wang YM. (2013). HMGB1 gene polymorphisms in patients with chronic hepatitis B virus infection. World J Gastroenterol. 19:5144-5149.
15. Köchl S, Niederstätter H, Parson W. (2005). DNA extraction and quantification of forensic samples using the phenol-chloroform method and real-time PCR. Methods Mol Biol. 297: 13–29.
16. Supic G, Kozomara R, Zeljic K, Stanimirovic D, Magic M, Surbatovic M, Jovic N, Magic Z. (2015). HMGB1 genetic polymorphisms in oral squamous cell carcinoma and oral lichen planus patients. Oral Dis. 21: 536-543.
17. Kaneko Y, Pappas C, Malapira T, Vale FL, Tajiri N, Borlongan CV. (2017). Extracellular HMGB1 modulates glutamate metabolism associated with kainic acid-induced epilepsy-like hyperactivity in primary rat neural cells. Cell PhysiolBiochem. 41: 947–959.
18. Chen R, Hou W, Zhang Q, Kang R, Fan XG, Tang D. (2013). Emerging role of high-mobility group box 1 (HMGB1) in liver diseases. Mol Med.19: 357-66.
19. Sopipong W, Tangkijvanich P, Payungporn S, Posuwan N, Poovorawan Y. (2011). The KIF1B (rs17401966) single nucleotide polymorphism is not associated with the development of HBV-related hepatocellular carcinoma in Thai patients. Asian Pac J Cancer Prev. 14: 2865-2869.
20. Kornblit B, Munthe-Fog L, Madsen HO, Strom J, Vindelov L, Garred P. (2008). Association of HMGB1 polymorphism with outcomes in patients with systemic inflammatory response syndrome. Crit Care. 12: 83.
21. Zeng L, Zhang AQ, Gu W, Chen KH, Jiang DP, Zhang LY, Du DY, Hu P, Huang SN, Wang HY, et al., (2011). Clinical relevance of single nucleotide polymorphisms of the high mobility group box 1 protein gene in patients with major trauma in southwest China. Surgery. 151:427–436.